Manuals+
Oxford Nanopore Technologies plc

Interim Results for the Six Months Ended 30 June 2025

Oxford Nanopore Technologies plc has announced its interim results for the six months ended 30 June 2025, detailing a period of strong performance across its global operations and diverse customer segments. The company achieved revenue growth ahead of expectations, supported by increased demand in both Research and Applied markets, and enhanced adoption of its PromethION platform.

CEO Gordon Sanghera highlighted the company's progress towards profitability and its strategic priorities, including advancements in product innovation, expanded multiomic capabilities, and a new strategic partnership with Cepheid focused on infectious disease sequencing solutions.

Strategic Progress and Future Outlook

Operational excellence initiatives and refined commercial strategies are in place to capture high-priority market opportunities. Oxford Nanopore Technologies has reaffirmed its financial guidance for fiscal year 2025 and its medium-term targets, underscoring confidence in its growth trajectory and long-term objectives.

For comprehensive details on the financial and operational performance, please visit the Oxford Nanopore Technologies investor relations portal.

PDF preview unavailable. Download the PDF instead.

ont-interim-results-2025-final

Related Documents

Preview Oxford Nanopore Technologies 2025 Interim Results Presentation - Financial Performance and Strategic Update
Detailed overview of Oxford Nanopore Technologies' financial performance for the first half of 2025, including revenue growth, profitability improvements, strategic progress across key markets, and future guidance. Features insights into R&D, operational efficiency, and platform benefits.
Preview PromethION 2 Solo Quick Start Guide
A concise guide to setting up and performing a hardware check on the Oxford Nanopore PromethION 2 Solo sequencing device, including connection, setup, and technical specifications.
Preview PromethION 2 Solo Quick Start Guide
A quick start guide for setting up and verifying the PromethION 2 Solo device, including pre-installation checks, device setup, hardware checks, and power-off procedures.
Preview Oxford Nanopore Service Provider Programme: Transform Services with Multiomic Insights
Learn how Oxford Nanopore's Service Provider Programme empowers labs to deliver advanced multiomic insights, attract service projects, and scale innovation with their cutting-edge sequencing technology and EPI2ME platform.
Preview Oxford Nanopore Large Cohort Sequencing Workflow for Clinical Research
Accelerate clinical research with Oxford Nanopore's PromethION 24 platform. This guide details a comprehensive workflow for large cohort genomic and epigenomic analysis, from DNA extraction to variant calling.
Preview Oxford Nanopore Technologies Sustainability Report FY 2024
Discover Oxford Nanopore Technologies' commitment to sustainability with their FY 2024 report, detailing their impact on Product, People, and Planet. Learn about their vision, mission, values, and how their innovative nanopore sequencing technology is driving advancements in science, health, agriculture, and conservation.
Preview Ligation Sequencing DNA V14 (SQK-LSK114) Protocol
A comprehensive protocol for Ligation Sequencing DNA V14 (SQK-LSK114) by Oxford Nanopore Technologies, detailing steps for DNA repair, end-prep, adapter ligation, library preparation, and flow cell setup for MinION and GridION devices.
Preview Rapid Whole-Genome Sequencing Workflow for Variant and Methylation Identification | Oxford Nanopore Technologies
An overview of the Oxford Nanopore Technologies Rapid WGS workflow for fast, end-to-end identification of pathogenic variants and methylation from blood samples using the PromethION 24. This PCR-free nanopore sequencing approach enables rapid turnaround times, comprehensive variant calling (SNVs, SVs, repeat expansions), and epigenetic analysis from a single dataset.